Geneva, Switzerland, February 1, 2024– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the launch of a private placement of ordinary shares to be issued by the Company, in connection with a share capital increase without preferential subscription rights of an indicative amount of €5 million by way of a private placement reserved to certain qualified investors, with an accelerated book-building; the offering will also include a public offering for retail investors, in France only through the PrimaryBid platform. The Company also announces its 2023 year-end cash position.